Grant Life Sciences Announces That U.S. Patent Will Be Issued for Blood Test That Detects Cervical Cancer

Share Article

Grant Life Sciences (OTC Bulletin Board: GLIF) announced today it has received notice from the U.S. Patent and Trademark Office that Patent No. 7,267,961--'PEPTIDES FROM THE E7 PROTEIN OF HUMAN PAPILLOMA VIRUSES 16 AND 18 FOR DETECTING AND/OR DIAGNOSING CERVICAL AND OTHER HUMAN PAPILLOMA VIRUS ASSOCIATED CANCERS'--will issue tomorrow, Tuesday, Sept. 11, 2007.

Of course we are extremely pleased by the issuance of this patent, which is an important part of a comprehensive IP portfolio focusing on HPV detection and diagnostic technologies, including domestic patents, international patents and patent applications, that Grant Life Sciences is overseeing

    "Of course we are extremely pleased by the issuance of this patent, which is an important part of a comprehensive IP portfolio focusing on HPV detection and diagnostic technologies, including domestic patents, international patents and patent applications, that Grant Life Sciences is overseeing," said Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist.

"No doubt, this is a very significant development for Grant Life Sciences," added Dr. Lin. "This patent would protect our investment to date in the development of our serum-based test for cervical cancer and allows us to move forward confidently in seeking an appropriate development-and-commercialization partner."

About Grant Life Sciences Inc.

Grant Life Sciences Inc., a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.

Forward-Looking Safe Harbor Statement

With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dr. Hun-Chi Lin
Grant Life Sciences
213-637-5692
Email >